Finch Therapeutics Group, Inc. battled to keep its microbiome-focused programs going through two workforce reductions in 2022, but now it appears to be ceding the fight. On 24 January, the Somerville, MA-based firm said it will reduce its headcount by roughly 95%, with the affected positions ending in February, and discontinue a Phase III trial of lead candidate CP101 in recurrent Clostridium difficile infections.
Finch said an assessment by its management team and board of directors determined that the company’s best route forward for its shareholders is to focus on realizing the value of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
